Clinical Trials Browser

Not yet recruiting × surufatinib × 90 days × Clear all

NCT07609121 2026-05-27

Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung